In vitro production of erythrocytes in physiologic numbers from human induced pluripotent stem cells (hiPSCs) holds great promise for improved transfusion medicine and novel cell therapies. We report here, for the first time, a strategy for scalable and xeno-free differentiation of hematopoietic stem/progenitor cells from hiPSCs and subsequent erythrocytes specification, by using stepwise cell culture conditions and by integrating spinner flasks and rocker. This system supported robust and reproducible definitive hematopoietic differentiation of multiple hiPSC lines. We demonstrated an ultra-high yield of up to 4×10 9 CD235a + erythrocytes at >98% purity when using a 1-litre spinner flask for suspension culture. Erythrocytes generated from our system can reach a mature stage with red blood cell (RBC) characteristics of enucleation, β-globin protein expression and oxygen-binding ability. The entire process is xeno-free and clinically compliant, allowing future mass production of hiPSC-derived RBCs for transfusion medicine purposes.
Introduction
As an irreplaceable clinical practice in modern medicine, red blood cell (RBC) transfusion saves lives of patients suffering from severe blood lose or chronic anemia. Accessibility and dependence on blood donation remain critical around the world. This is a particularly important issue for the patients who need RBCs of rare blood types, because of severe complications caused by mismatching transfusion or allo-sensitized responses among chronically transfusiondependent patients 1 .
A potential solution is to manufacture RBCs from hematopoietic stem and progenitor cells (HSPCs) that are isolated from patients themselves or donors with desirable blood types.
Recently, mature RBCs that were generated ex vivo from CD34 + HSPCs were transfused into a volunteer to demonstrate in vivo safety 2 , albeit at limited quantity (~4×10 10 RBCs or ~2% of one transfusion unit). One major challenge for clinical applications has been how to expand HSPCs extensively because committed erythroid progenitors have limited proliferative potential before differentiating into mature RBCs 3 .
Human induced pluripotent stem cells (hiPSCs) is a promising cell source that can be easily derived from donor somatic cells and expanded indefinitely 4 . They would provide a potentially unlimited source of RBCs perfectly matching to patients or a favorable donor with any antigen types, especially the universal donor type O and Rhesus D-negative (O Rh-) and rarephenotype matching RBCs [5] [6] [7] [8] . Recently, hiPSCs derived from healthy donors or patients with blood-related disorders were successfully differentiated towards erythroid lineages and completed terminal maturation, which is marked by enucleation, blood antigen display, fetal-toadult hemoglobin switch, functional oxygen carrying ability and many other characteristic features comparable with primary blood cells or those derived from primary HSPCs [9] [10] [11] [12] [13] .
The current methodology for the in vitro generation of RBCs from hiPSCs generally includes three distinguishable steps: (1) formation of definitive HSPCs that express both CD34 and CD45 markers (CD34 + CD45 + ); (2) erythroblast specification and expansion; and (3) erythrocyte maturation. To complete step (1), various protocols were established to promote mesodermal commitment and hematopoietic specification of hiPSCs 14 . For example, co-culturing with mouse stromal cells 9, 15, 16 or human stromal cells [17] [18] [19] harbored hiPSCs or HSPCs in stromal niches that recapitulated the in vivo environments of hematopoiesis, and sometimes was integrated together with the latter two steps. Efficient feeder-free differentiation of hiPSC in monolayer adhesion culture on supporting substrates has not been established until a recent study showed that tenascin C could replace confluent OP-9 mouse stromal cell line, although the erythrocyte production from the new culture system has not been demonstrated 20 . The most commonly used method for step (1) so far is by forming embryoid bodies (EBs) that are self-organized to mimic early human embryonic structures and development 21 . The mesodermal commitment and haematopoietic differentiation with EBs are further enhanced by adding exogenous cytokines such as bone morphogenetic protein 4 (BMP4), fibroblast growth factor 2 (FGF2), stem cell factor (SCF), vascular endothelial growth factor (VEGF), interleukin-3 (IL-3), etc. 12 In this study, we aim to establish a scalable system that can support large-scale EB differentiation towards hematopoietic lineages and high-yield erythrocyte production from hiPSCs in vitro. To achieve this goal, we first sought to combine the expansion of undifferentiated hiPSCs and the formation of EBs in suspension using spinner flasks. Then we integrated this process with static and dynamic culture on a platform rocker to enhance the efficiency of HSPC generation. HSPCs differentiated in the scalable system were directly induced to generate mature erythrocytes in suspension in scalable settings.
Results

E8-based Medium in Spinner Flasks is a Superior Condition for Initiating Scalable EB Formation
Utilizing our scalable expansion of undifferentiated hiPSC in suspension, which is matrixindependent and microcarrier-free 36 , we transitioned to volumetrically scalable EB differentiation using vessels such as a spinner flask (SF) and a tissue culture flask on a platform rocker (TR).
A culture in spinner flasks can be directly scale-up into large stirred tank bioreactors, whereas a culture in TR condition is suitable for straightforward scale-up into a WAVE bag bioreactor.
Shear stress on hiPSCs in the suspension culture in agitating vessels is known to affect cell survival 37 . Medium flow in a SF and TR generate different levels of shear stress. Thus we first tested which scalable system better support EB formation from a single cell suspension from BC1 hiPSCs 38 . We found that the serum-free medium (SFM) used in the standard forced aggregation (FA) differentiation for the first 2 days 30 could not support consistent bulk EB formation in suspension culture especially in spinner flasks, resulting in an unexpected high level of cell death with cell viability below 65% (Fig. 1a) . In contrast, EBs formed with a modified E8-based medium supplemented with human albumin and the same amount of BMP4 and a ROCK inhibitor Y27632 as the SFM (called E8-EB medium thereafter) showed significantly higher cell viability, 89±4 % on EB day 1 (Fig. 1a) , while with similar total cell yield (data not shown). It demonstrated a simple but efficacious approach to reduce cell death during EB formation in spinner flasks causing by shear force. We also found that EBs formed in the E8-EB medium in spinner flasks were more uniform in size, while many large EBs with irregular shapes formed on rocker likely due to insufficient and uneven agitation (Fig. 1b) . Quantitative analysis of EB size indicated that EBs formed in spinner flasks have a homogeneous size with an average equivalent diameter of 187±36 µm, whereas a wider distribution of EB size was found on rocker (247±128 µm) with many compact EBs larger than 400 µm (Fig. 1c) , which would cause cell death in the center due to insufficient transport of nutrient, waste and O 2 . Therefore, we chose to use E8-EB medium in spinner flasks as the optimized condition to form spatially and temporally synchronized EBs.
An Optimized integration of Static Culture and Spinner Flasks Facilitates Scalable
Generation of Hematopoietic Cells
The yield from one bioreactor run (indicated as "batch yield") is an essential parameter to measure outcomes in the scale-up process. In order to maximize the yield of the EB differentiation, we explored several strategies using SF and TR (Fig. 2a) , based on media and timeline modified from the FA method previously established 30 . After formed in spinner flasks, EBs harvested on day 3 were cultured either in spinner flasks or on rocker. In one condition, a 3-day static culture in tissue culture flasks (TS, see illustration in Fig. 2a ) was also applied between the spinner and the rocking condition (SF-TS-TR). We compared the yield of suspension cells released from EBs (harvested at day 13) in batches with 40-ml initial volume followed by different combinations of these module conditions (Fig. 2a) . From four independent experiments in each condition, the conventional FA method generated 10.2±4.2×10 6 live cells from eight 96-well plates starting from 40-ml of initial single cell suspension (Fig. 2b) . With the same initial volume, the methods in which EBs were in free suspension throughout the culture (such as SF, TR and SF-TR, see Fig. 2a ) showed poor reproducibility with about 50% of experiments failing to generate hematopoietic cells. Only the combinatorial SF-TS-TR strategy including a 3-day static culture in tissue culture flasks supported more consistent differentiation with higher yields. A total of 29.1±10.8 ×10 6 live cells were generated from SF-TS-TR suspension, 2.9-fold higher than the FA control (Fig. 2b) .
Next, we investigated the potential mechanisms underlying the improvement in yield when using SF-TS-TR strategy. The three days of static culture was the only difference between SF-TS-TR and SF-TR. Light microscopy images revealed distinguishable changes of EB morphology and confirmed the emergence of HSPC on day 13 ( Supplementary Fig. S1 and 
Single Cells from Scalable EB Differentiation Are Characterized as HSPCs
Recently, we showed that the addition of 20 ng/ml Romiplostium (a thrombopoietin or TPO analog commercialized as Nplate®) during the last stage of EB-mediated differentiation (day 11 to day 14) increased CD34 + CD45 + HSPCs yield using the conventional FA method, and also enhanced subsequent megakaryocytic differentiation as a replacement of TPO 30 . In the current study, we also found that adding Nplate on day 11 to the SF-TS-TF culture also increased the numbers of total and CD34 + CD45 + HSPCs of suspension cells harvested at day [13] [14] ( Supplementary Fig. S3 ). Therefore, we included the Nplate treatment (one dose added at day 11) in the combinatorial SF-TS-TR strategy as well as all the FA control experiments (Fig. 2a) . (Fig. 3a) . The batch yield of CD34 + CD45 + cells from SF-TS-TR was 14.6±4.5×10 6 , which was significantly higher than the non-scalable FA method (Fig. 3b ).
Colony-forming unit (CFU) assay was performed to test the level of hematopoietic progenitor cells in the total and CD34 + purified suspension cell populations (Fig. 3c ). These results indicated that the CD34 + CD45 + cells generated from SF-TS-TR had comparable contents of myeloid and erythroid progenitor cells as the FA method.
Scalable System Supports Large-scale Erythroid Differentiation and Terminal Maturation
In previous studies, we reported a feeder-free static suspension condition for the generation of matured erythrocytes from the single cells of EB day 13 through two continuous steps of erythroid differentiation (ED) and terminal maturation (TM) 10 . Here we report the enhancement of the scalability of these two steps by applying dynamic suspension culture in scalable conditions (SF or TR, see the illustration in Fig. 2a ). Considering that >70% of the suspension cells were CD34 + cells, we found that it was not necessary to isolate CD34 + cells for downstream erythroid production under a culture condition selectively favoring erythroid cell proliferation and differentiation. After EB formation and initial hematopoietic differentiation ( Fig.   2a ), single cells were harvested at day 13 by passing the entire culture through a 40-µm cell strainer and immediately transfer to the following differentiation steps. This simple "filter-and-go" process would be highly favorable for the scale-up bioprocess. Previous studies found that even mild agitation at 15-20 rpm in stirred tank bioreactor had significant impact on the ex vivo erythropoiesis of peripheral blood CD34 + derived cultures 43 . We also confirmed that shear stress generated by agitation at medium speed range (40-50 rpm) in spinner flasks impeded the expansion rate of erythroid expansion and differentiation (Fig. 4a) . By reducing the agitation to low speed range in SF (22.5 rpm) or TR at low rocking frequency (10-15 rpm), expansion in erythroid differentiation and terminal maturation were recovered and comparable as in the static condition, calculated at 211±22 fold and 237±56 fold increase, respectively (Fig. 4a) .
We compared the yield of erythrocytes from the process in scalable system (using SF-TS-TR for EB differentiation and SF or TR for ED-TM steps) and non-scalable system (using FA in 96-well plates for EB differentiation and static suspension culture for ED-TM steps 10 ). The scalable process yielded 3.2±0.6×10 9 CD235a + erythrocytes, 1.5-fold higher than those from the non-scalable process (Fig. 4b) . After scale-up to 1-litre spinner flasks, we achieved an ultra-high yield of 4.1×10 9 hiPSC-derived erythrocytes starting from a 40-ml SF-TS-TR batch of EB differentiation. Taking these steps together, we established a complete procedure for the scalable production of human erythrocytes (Fig. 2a) . A cell suspension containing 1×10 9 cells in 10 ml PBS showed red color like diluted blood (Fig. 4c ).
Phenotypic changes in the suspension cells from SF-TS-TR during the scalable ED-TM steps were tracked by flow cytometry ( Fig. 4d and Supplementary Fig. S4 ). Plots of forward scatter and side scatter showed that the erythroblasts shrunk in size during the maturation period ( Supplementary Fig. S4a ). The gradual loss of CD45 and gain of CD235a expression indicated the loss of multipotent HSPCs and myeloid cell populations, and enrichment of erythroid population (Fig. 4d) S4b ) and no cells express lymphoid markers (data not shown). These data collected a highly pure population of erythrocytes as early as day 6 of TM. Enucleation (removal of nuclei) rate was measured by staining DNA with DRAQ5, followed by flow cytometry (Fig. 4e) . Erythrocytes from SF-TS-TR showed 2.8%-11.1% of enucleation rates from multiple experiments, similar to the same batch of FA control group and the range of variation. The enucleated cells remained metabolically active and with intact cell membrane (Fig. 4f ) and expressed hemoglobin protein (Fig. 4g) .
Scalable Strategy Supports Robust and Reproducible Generation of Erythrocytes from
Multiple hiPSC Lines
In order to test the robustness and reproducibility of the scalable differentiation system, we repeated the process in two other hiPSC lines (TNC1 and E2) using the same SF-TS-TR protocol. TNC1 was derived from human erythroblasts that were established from the peripheral blood mononuclear cells of a sickle cell disease patient, while E2 was derived from human mesenchymal stem cells that were established from the bone marrow mononuclear cells of a healthy donor. Both hiPSC lines accomplished efficient and high-yield generation of HSPCs, erythroblasts and erythrocytes (Table 1 and Supplementary Fig. S5 ), confirming the robustness and adaptability of the scalable differentiation system.
Erythrocytes Generated from the Scalable System Show Adult Hemoglobin Expression and Oxygen Carrying Function
We analyzed the expression of hemoglobin genes particularly β-globin gene at both mRNA and protein levels. The mRNA level increased dramatically along the differentiation. On TM day 7, cells from SF-TS-TR showed similar mRNA level of HBB and HBG as erythrocytes derived from cord blood CD34 + cells that were induced ED-TM in the same medium and scalable settings (Fig. 5a ). We further found that ~64% of TM day 7 cells from SF-TS-TR contained β-globin, while nearly 100% of the cells expressed γ-globin (Fig. 5b) . These cells produced β-globin in the similar level as those from FA ( Fig. 5b-c) .
We also determined whether the hemoglobin in the cells was functional to bind to O 2 molecules at high concentration and release them at low concentration. Oxygen-hemoglobin dissociation curve of BC1-derived erythrocytes in scalable settings were measured and found to be similar to the curve of primary cord blood RBCs (Fig. 5d) . Interestingly, TM day 6 cells from SF-TS-TR method (P 50 = 19.2 mmHg) showed lower O 2 binding affinity than those from FA method (P 50 = 16.1 mmHg), and were closer to cord blood (P 50 = 24.0 mmHg). It is known that fetal hemoglobin has a higher affinity to bind to O 2 and that cord blood express both fetal and adult hemoglobin. This result is consistent with the data that the content of fetal hemoglobin in the erythrocytes from SF-TS-TR was lower than erythrocytes from FA method, but still higher than in cord blood.
Discussion
Along with the flourish of transformative hiPSC technologies, cell culture conditions for scalable expansion of undifferentiated hiPSCs have been improved significantly 37, [45] [46] [47] .
Chemically defined, feeder-and xeno-free culture media and substrates are able to support long-term and scalable expansion of hiPSCs while keeping a normal karyotype as we have demonstrated 48 . These improvements suggest a bypass to the elusive goal of ex vivo expansion of human HSPCs, especially long-term stem cell activities, which remains challenging 3 . In this way, one can expand undifferentiated hiPSCs first into a large number followed by a large-scale and high-efficiency differentiation process of HSPC production, to achieve a high yield of a final blood cell product such as erythrocytes. During this multi-step differentiation process, the generation of HSPCs from hiPSCs that are able to generate multiple types of mature hematopoietic cells is the rate-limiting step 14 . In the current study, we demonstrated the first complete procedure for scalable production of erythrocytes from hiPSCs under a feeder-free and xeno-free culture condition, with an innovative EB differentiation step.
The current success was based on our previous study where we demonstrated that hiPSCs can form cell spheres of an average equivalent diameter of ~200 µm in spinner flask culture under an optimized speed in E8 medium 36 . Each sphere contains approximately 3,000 cells, which correspond to the optimized number of input hiPSCs to form one EB per well in the FA EB formation method. For the EB formation in suspension in differentiation medium, we found that cell viability on day 1 was a critical checkpoint for differentiation efficiency, because apoptotic or dead cells wrapped inside the EBs would lead to break or failure of EB formation.
hiPSCs seeded as single cells on day 0 were most vulnerable to shear-induced cell death, whereas insufficient shear would cause agglomeration and lead to transfer deficiency of O 2 , nutrients and metabolic wastes. Therefore, we sought to find a balance by choosing the appropriate platform and optimizing the agitating speed and culture medium formulation for EB formation in the critical first two days. We also found that different hiPSC lines had distinct sensitivity and tolerance to shear stress in spinner flasks, indicated by cell survival and EB sizes.
Some iPSC lines such as BC1 and E2 survived poorly in spinner culture with the SFM-EB medium, even in slow agitation. To overcome this, we reported here that a new EB medium (based on the original E8 medium used for expanding hiPSCs) significantly enhanced the cell survival in spinner flasks. Moreover, we observed that physiological O 2 tension (5%) that was known to enhance hiPSC survival also enhanced EB formation and differentiation, using an oxygen monitoring and controlling system (unpublished data, 2014-2015). It was reported that the dissolved O 2 level in the media affected the rate and maturation of erythroblasts in vitro 49 .
This oxygen monitoring and controlling system would also provide a suitable apparatus for further optimization of erythrocyte terminal differentiation by tuning O 2 tension in the culture. The SF-TS-TR method requires 8.3-fold more input of hiPSCs per run than the FA method to initiate EB differentiation in current settings, which causes about 3-fold decrease in the efficiency of CD235a + erythrocyte generation per input hiPSC on TM6. However, the batch yield is still about 2-fold higher. More importantly, the scalability of the SF-TS-TR system enables a volumetric scale-up process using 100-litre to 500-litre stirred tank bioreactors and rocking bag bioreactors, which is more preferable in the manufacture concept other than the linear scale-out process of using the FA method. By one batch of hiPSC differentiation, we generated 4.1×10 54 , the concept and improvement demonstrated in our study is an important step forward leading to a feasible solution of reducing manufacturing cost by expanding production scale. Substantial improvement of medium that can support higher differentiation efficiency and culture density would be very helpful to further manufacturing purpose.
The HSPCs generated from this scalable system were confirmed to exhibit comparable phenotype and potential for multi-lineage differentiation as the HSPCs from the FA method that were extensively evaluated in the previous studies 10 . Despite the substantially increased contents of functional hemoglobin, the enucleation rate (2%-15%) we achieved so far was still low as compared to those derived from primary CD34 + CD45 + cells from cord blood and bone marrow. The enucleation rate also varied among hiPSC lines (and from batch-to-batch to a less degree), which is a shared problem among other studies on hiPSC-derived erythrocytes 9, 12, 55 .
Although some studies suggested that the erythroblasts generated in vitro could eventually enucleate in circulation when being injected in vivo 55 , it would be ideal to reach full enucleation and eliminate all nucleated cells before being transfused into recipients. More efforts are needed to further improve the enucleation of hiPSC-derived erythrocytes. Recent reports on transcription profile of enucleating erythroblasts derived from cord blood CD34 + cells 44 and hESCs 56 provide an insight in the molecular signature of the enucleation process and may lead us to find more efficacious solutions to improve enucleation in suspension culture conditions.
In summary, we generated erythrocytes from three hiPSC lines in a scalable differentiation system that combined spinner flask and rocker for EB differentiation. We achieved high batch yield, β-globin expression and complete terminal maturation in the hiPSC-derived erythrocytes.
The ease of operation, the simplicity of cytokine combination and the high level of chemical definition of the components added favorable features to this system in a scale-up point of view.
Furthermore, because all the components used in our system for the entire expansion and differentiation process are formulated with recombinant human proteins, Food and Drug Administration (FDA)-approved biologics, or materials from human sources, this xeno-free and cGMP-compliant system provides the opportunity to produce clinical-grade erythrocytes from hiPSCs in a large-scale bioprocess for therapeutic purposes. Therefore, this study is a significant step forward towards the goal of large-scale generation of RBCs for therapeutic purposes.
Methods
EB Differentiation Using SF-TS-TR Method
BC1 and TNC1 hiPSCs were expanded in 100-ml spinner flasks (CELLSPIN, Integra Biosciences) as cell aggregates in E8 medium (Essential 8, Thermo Fisher Scientific) as previously described 36 to yield a large quantity. Cell aggregates were dissociated into single cells by Accutase and inoculated at 4 × 10 5 cells/ml in spinner flasks at agitating speed of 35-50 rpm to initiate EB formation in 40 ml E8-based EB-formation medium (E8-EB medium), which is E8 medium supplemented with 10 ng/ml BMP4 (R&D Systems), 0.5% w/v human albumin (Plasbumin-25, Amgen), and 10 µM ROCK inhibitor Y27632 (Stemgent). This was marked as day 0 of differentiation. On day 1, stop agitation, settle the EBs at the bottom of the flask, and change ~70% of the medium with fresh E8-EB medium to remove dead cells. All medium was replaced by SFM-based EB differentiation medium 30 on day 2. On day 3, we transferred the culture into a 150-cm 2 tissue culture flask, and placed in static (TS). After changing medium on day 6, we put the tissue culture flask on a platform rocker at a frequency of 10-15 rpm (TR).
Then we changed ~70% of the medium on day 8, day 10, and day 13. Nplate (Amgen) were added at a final concentration of 20 ng/ml in EB differentiation medium from day 11 to day 13 to enhance HSPC expansion. Single suspension cells were harvested on day 13 and sequentially cultured in erythroid differentiation medium that was also made xeno-free by replacing bovine serum albumin (BSA) with human albumin, with the same concentration of cytokines and holotransferrin for 10 days as previously described 10 , followed by terminal maturation for 6-8 days 10 , in either TR or SF condition with low agitating speed. FA method (so called "spin-EB") was applied as positive control as previously described 30 . When calculating yield, one batch of FA control was set as 8 plates of 96-well plates for the same 40-ml initial medium volume.
Erythroid Differentiation and Terminal Maturation
Suspension cells harvested from EB day 13 were directly transferred into an erythroid liquid culture in tissue culture plates in static condition, on rocker, or in spinner flasks without the need of CD34 + isolation. The medium formulations for erythroid differentiation and terminal maturation were described previously 10, 31 , except that the BSA in SFM was replaced by human albumin to make it xeno-free 30 .
Additional methods can be found in the Supplementary Information.
Statistics
All analysis of cell number, cell viability, EB size, and flow cytometry were collected from at least three independent experiments (n ≥ 3). Real-time quantitative PCR analysis was performed in two independent experiments with triplicate technical replicates each. The unpaired two-tailed Student's t-test or two-way analysis of variance (two-way ANOVA) followed by Bonferroni's posttest was done using GraphPad Prism 5 for the comparison between two groups or multiple groups, respectively. Data are presented as mean ± s.d. if not specified.
Significance level was assigned as not significant (n.s.) P > 0.05, * P < 0.05, ** P < 0.01, and *** P < 0.001.
Supplementary Information
Supplemental (a) Levels of cell viability on day 1 using different media for EB formation in suspension cultures.
All media were supplemented with 10 µM Y27632 to promote cell survival. SFM-EB: serum-free medium with BMP4 and FGF2 as the medium used in the FA control of EB formation; E8-EB:
E8 medium with BMP4 and human albumin (n = 3 independent experiments, mean ± s.d.). (d) Oxygen-hemoglobin dissociation curves of TM7 cells derived from non-scalable and scalable process measured by a Hemox Analyzer, using primary cord blood red blood cells as a control.
